Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line

100 patients with metastatic and/or advanced renal cell carcinoma treated with sunitinib (Sutent) will be inclued and followed with standard care plus a call center

Principal assumption : the proportion of patients presenting with at least one grade 3 or 4 AE (whether related to sunitinib or not).

RENACALL is a prospective intermediate care study whose main aim is to evaluate the impact of a therapy management platform on the management of patients suffering from advanced/metastatic renal cell carcinoma and receiving first line treatment with Sutent®.

100 mRCC patients treated receiving first line Sutent® treatment shall be included in the study, and shall benefit both from conventional follow-up and from additional therapy management platform-based follow-up. Platform follow-up shall consist in regular phone calls to accompany patients in their real life home management of their treatment with sunitinib (prevention, advice and guidance of patients towards options)..

• Other: Best supportive care
  BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
• Other: call center
  Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.

Inclusion Criteria:

Man or woman aged 18 or over;

• Patient suffering from a/mRCC, receiving sunitinib first-line treatment, as per SPC recommendations;
• Resolution (grade ? 1 according to CTCAE version 4.03 of June 2010) of all acute toxic effects due to radiotherapy or surgical procedure prior to initiation of sunitinib;
• Patient who can be monitored for 6 months.
• Female patient of child-bearing age using a form of contraception during treatment with Sunitinib and for at least 28 days after termination of treatment with Sunitinib;
• Patient having signed his/her consent form;
• Patient affiliated with a social security scheme.

Non-inclusion criteria

• Patient participating in a clinical trial during sunitinib treatment;
• Patient managed by a home hospitalisation service during sunitinib treatment;
• Patient taking part in therapeutic education programmes, or benefiting from nursing consultation, or from any other significant treatment support and likely to impact adverse event management.
• Patient untreated and/or symptomatic brain metastases prior to sunitinib initiation;
• Patient refusing the use of his/her personal data.
• Patient with an ECOG performance status upon inclusion > 2;
• Patient presenting with a serum creatinine level >1.5 times the upper limit of the normal level;
• Patient presenting with a bilirubin level > 2 mg/dl, aspartate transaminase (ASAT) or alanine transaminase (ALAT) >2.5 times the upper limit of the normal value, or >5 times the upper limit of the normal value in the presence of liver metastases upon initiation of sunitinib treatment.
• Patients who are staff members of a centre involved in the study, or close to one of the staff members of a centre directly involved in conducting the study, or patients employed by Pfizer and involved in conducting the study